Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Sep 6;6(5):456-457.
doi: 10.1016/j.ijwd.2020.09.001. eCollection 2020 Dec.

Bullous pemphigoid in a metastatic lung cancer patient associated with nivolumab

Yuka Maya  1 , Reine Moriuchi  1 , Yuka Takashima  1 , Moeko Hotta  1 , Hiroshi Izumi  2 , Satoko Shimizu  1
Affiliations
Case Reports

Bullous pemphigoid in a metastatic lung cancer patient associated with nivolumab

Yuka Maya et al. Int J Womens Dermatol. .

Erratum in

  • Erratum regarding previously published articles.
    [No authors listed] [No authors listed] Int J Womens Dermatol. 2021 Sep 28;7(5Part B):868. doi: 10.1016/j.ijwd.2021.09.012. eCollection 2021 Dec. Int J Womens Dermatol. 2021. PMID: 35028406 Free PMC article.
No abstract available

Keywords: Bullous pemphigoid; Lung cancer; Nivolumab; irAEs.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
(A) Pruritic edematous plaques and tense bullae over the entire body; (B) histological examination revealing vacuolar changes at the dermal-epidermal junction with eosinophilic infiltration in the dermis; (C) direct immunofluorescence showing linear C3 deposition at the dermal-epidermal junction. A consent form for the use of the photo was obtained from the patient.
See this image and copyright information in PMC

References

    1. Anastasopoulou A., Papaxoinis G., Diamantopoulos P., Christofidou E., Benopoulou O., Stratigos A. Bullous pemphigoid-like skin lesions and overt eosinophilia in a patient with melanoma treated with nivolumab: case report and review of the literature. J Immunother. 2018;41(3):164–167. - PubMed
    1. Hirotsu K., Chiou A.S., Chiang A., Kim J., Kwong B.Y., Pugliese S. Localized bullous pemphigoid in a melanoma patient with dual exposure to PD-1 checkpoint inhibition and radiation therapy. JAAD Case Rep. 2017;3(5):404–406. - PMC - PubMed
    1. Hwang S.J.E., Carlos G., Chou S., Wakade D., Carlino M.S., Fernandez-Penas P. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. Melanoma Res. 2016;26(4):413–416. - PubMed
    1. Jour G., Glitza I.C., Ellis R.M., Torres-Cabala C.A., Tetzlaff M.T., Li J.Y. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol. 2016;43(8):688–696. - PubMed
    1. Lopez A.T., Khanna T., Antonov N., Audrey-Bayan C., Geskin L. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol. 2018;57(6):664–669. - PubMed

Publication types